Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I clinical trials for its new fourth-generation EGFR inhibitor, TQB3002. This innovative drug, designed to tackle drug resistance in non-small cell lung cancer, has shown promising preclinical results in inhibiting tumor growth. The company is keen to expand its international presence and accelerate the clinical development of TQB3002.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
